m+Medelevator.RU
← Поиск публикаций
Frontiers in cardiovascular medicine · 2025

Enhanced recovery in type A aortic dissection evaluating the efficacy and feasibility of early myocardial reperfusion.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Niu Tianyu, Liu Zhishuo, Liu Yu, Yang Zhonglu, Ge Yuguang, Wang Lu, Xia Lin, Jiang Hui

Аннотация

BACKGROUND: This study investigates the feasibility and early outcomes of early myocardial reperfusion in patients with type A aortic dissection (TAAD), evaluating its effectiveness and potential benefits compared to traditional cardioplegic arrest techniques.

METHODS: A retrospective analysis was conducted on 168 patients diagnosed with TAAD who underwent surgery at the General Hospital of the Northern Theater Command in China from January 2021 to July 2024. Patients were divided into two groups: early myocardial reperfusion (EMR group, n = 66) and cardioplegic arrest (CA group, n = 102). Perioperative outcomes were compared between the groups.

RESULTS: Early myocardial reperfusion significantly reduced ventilation time 23.08 (18.21, 66.74) hours vs. 48.58 (19.18, 122.97) hours, P < 0.05], ICU stay time [58.80 (21.20, 126.68) hours vs. 84.86 (41.12, 168.81) hours, P < 0.05], and hospitalization time [13.00 (10.00, 16.00) days vs. 15.00 (11.75, 19.00) days, P < 0.05] compared to the CA group. There was no significant difference in hospital costs, first-hour chest tube drainage, left ventricular ejection fraction, or postoperative adverse events between the groups, except for the rate of CRRT treatment, where the EMR group had significantly fewer patients requiring postoperative CRRT (10.6% vs. 23.5%, P < 0.05).

CONCLUSION: This study demonstrates that early myocardial reperfusion is a feasible and effective technique for TAAD, offering considerable advantages in reducing ventilation time, ICU stay, hospitalization duration and postoperative renal insufficiency.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты